Ebola viruses represent a unique challenge in global public health, combining high transmissibility in healthcare settings with severe clinical manifestations and substantial mortality. ^[19] First identified in 1976 during simultaneous outbreaks in Sudan and the Democratic Republic of the Congo, Ebola viruses have remained a persistent threat to populations in Central Africa, with periodic outbreaks occurring at irregular intervals. The 2014–2016 West African epidemic demonstrated the pandemic potential of these pathogens, resulting in more than 11,000 deaths and exposing critical gaps in diagnostic capacity, therapeutic availability, and infection prevention and control protocols.

The most recent Public Health Emergency of International Concern (PHEIC) declaration on May 16, 2026, pertains to an epidemic caused by Bundibugyo ebolavirus (BDBV) ^[21] in the Ituri Province of the Democratic Republic of the Congo (DRC) and neighboring Uganda. As of mid-May 2026, eight laboratory-confirmed cases and 246 suspected cases with approximately 80 suspected deaths have been reported, predominantly in Ituri Province. ^[21] Notably, two laboratory-confirmed imported cases have been identified in Kampala, Uganda, linked to cross-border travel from Ituri; no local onward transmission has been documented in Uganda to date. This outbreak occurs amid significant security challenges and limited healthcare infrastructure, factors that substantially elevate transmission risk and complicate containment efforts.

Ebola viruses (genus Orthoebolavirus, family Filoviridae) are enveloped, non-segmented, negative-sense, single-stranded RNA viruses approximately 19 kb in length. ^[1] The genome encodes seven structural proteins in the order: NP–VP35–VP40–GP–VP30–VP24–L. This linear arrangement is not merely organizational; it reflects functional interdependencies in viral transcription, replication, and assembly.

The nucleoprotein (NP) is the most abundant structural protein, encapsidating the viral RNA to form the ribonucleoprotein (RNP) complex. Within the RNP, NP binds cooperatively to viral RNA, while VP35 serves as a cofactor for the RNA-dependent RNA polymerase (L), facilitating both transcription of individual mRNAs and replication of the entire genome. ^[1] VP30 acts as a transcription factor, regulating the switch between transcription of individual viral genes and encapsidation of full-length genomic RNA.

The glycoprotein (GP) is synthesized as a precursor protein (GP₀) that undergoes proteolytic cleavage by the host protease furin. This processing generates two disulfide-linked subunits: GP1 (approximately 120 kDa), which contains the receptor-binding domain, and GP2 (approximately 40 kDa), which mediates membrane fusion. ^[3] The mature GP forms chalice-shaped trimers displayed on the virion surface, with the apex of the chalice containing the receptor-binding sites.

Viral entry occurs via macropinocytosis and subsequent cathepsin-mediated proteolytic processing within endosomal compartments. GP1 binds to Niemann-Pick C1 (NPC1) protein, a lysosomal cholesterol transporter, which serves as the primary cellular receptor for Ebola viruses. ^[20] Upon endosomal acidification, conformational changes in GP expose a fusion loop in GP2, which inserts into the host cell membrane. GP is the primary target for neutralizing antibodies and vaccine development.

The matrix protein VP40 is the most abundant structural protein in mature virions and serves as the primary driver of virion assembly and budding. ^[4] VP40 exhibits intrinsic membrane-binding properties and can oligomerize independently, forming lattice-like structures beneath the viral envelope. The protein contains distinct domains that mediate membrane binding, oligomerization, and interactions with host cell machinery including ESCRT (Endosomal Sorting Complex Required for Transport) components, which facilitate membrane deformation and virion release.

Late domains within VP40 recruit L-domain binding partners such as TSG101 and ALIX, proteins normally involved in cytokinesis and endocytic trafficking. This interaction with cellular ESCRT machinery allows the virus to exploit the host cell's own membrane topology machinery to drive virion separation from the cell membrane. Disruption of this interaction significantly impairs virion release, highlighting the essential role of VP40-ESCRT interactions in the viral life cycle.

VP35 inhibits type I interferon (IFN-α/β) production through multiple mechanisms. ^[8] It binds to double-stranded RNA (dsRNA) generated during viral replication, preventing recognition by cellular pattern recognition receptors including RIG-I and MDA5. Furthermore, VP35 directly blocks phosphorylation and activation of IRF3, a master transcription factor for interferon-β production. ^[24] These multiple layers of inhibition result in profound suppression of type I interferon responses, a critical factor enabling viral replication unchecked in the earliest phases of infection.

VP24 specifically inhibits the Janus kinase (JAK)–Signal Transducer and Activator of Transcription (STAT) pathway by preventing nuclear translocation of phosphorylated STAT1 and STAT2. ^{[5], [6], [9]} This selective inhibition of STAT signaling creates a situation where even if some interferon is produced, the cell cannot respond appropriately to it. Recent structural studies have revealed that Ebola virus can sequester IRF3 within viral inclusion bodies, preventing its activation even in the context of other signals. ^[7]

Current evidence strongly indicates that fruit bats of the family Pteropodidae serve as the natural reservoir for Ebola viruses. ^{[19], [20]} Multiple species, including Eidolon helvum (straw-colored fruit bat), Epomops franqueti (singing fruit bat), and Myonycteris torquata (little collared fruit bat), have tested positive for Ebola virus RNA or antibodies. These bats do not manifest clinical disease despite harboring the virus, suggesting co-evolutionary adaptation between bat immune systems and filoviral pathogens.

Spillover events to humans occur through direct contact with infected bats, consumption of bat bushmeat, or contact with intermediate mammalian hosts, particularly great apes (chimpanzees and gorillas) and forest antelopes. ^[20] Several documented EVD outbreaks have been preceded by die-offs of great apes, suggesting these animals serve as amplifying hosts and sources of human infection. Occupational exposure among hunters and bushmeat processors represents a significant risk factor for zoonotic transmission in endemic regions.

Six recognized Ebola virus species are now acknowledged: Zaire (EBOV), Bundibugyo (BDBV), Sudan (SUDV), Taï Forest (TAFV), Reston (REBOV), and Bombali (BOMBV). ^[20] Of these, EBOV, BDBV, SUDV, and TAFV are known to cause human disease. Reston virus has caused disease in non-human primates but has never been documented to cause human illness. Bombali virus pathogenicity in humans remains uncertain, though it has been detected in bats. ^[13]

Once human infection is established, onward transmission occurs exclusively through direct contact with blood or body fluids of symptomatic (and highly viremic) patients. ^[19] The primary transmission routes are percutaneous exposure (puncture wounds, cuts, abrasions), contact with mucosal surfaces, and, to a lesser extent, exposure to respiratory secretions during close contact with symptomatic individuals. Ebola virus has been detected in diverse body fluids including saliva, tears, urine, feces, sweat, and vomitus.

Healthcare-associated transmission (HCAI) represents a particularly important epidemiological feature of Ebola outbreaks. ^[22] In the absence of rigorous infection prevention and control (IPC) measures—including appropriate use of personal protective equipment (PPE), hand hygiene, and safe injection practices—healthcare settings become amplification sites. The 2014–2016 West African epidemic demonstrated that nosocomial transmission could drive exponential outbreak growth.

The current BDBV epidemic represents a unique epidemiological challenge distinct from previous EBOV outbreaks. ^[14] BDBV, first identified in 2007 in Uganda and subsequently associated with sporadic cases in Uganda and DRC, exhibits a lower historical case-fatality rate (approximately 30–50%) compared to EBOV (up to 90% in some outbreaks). ^{[13], [14]} However, no licensed vaccine or specific therapeutics against BDBV are available; while experimental BDBV vaccine candidates have shown promise in preclinical models, their cross-protective efficacy against BDBV in humans remains uncertain. ^{[11], [16]}

As of May 2026, confirmed cases in Ituri Province include healthcare workers, family members of infected individuals, and persons with unspecified exposure histories. ^[21] The outbreak likely originated in the Mongbwalu Health Zone, a high-traffic mining area, with a significant detection gap of approximately three weeks between the presumed index case (symptom onset ~April 25, 2026) and laboratory confirmation (May 15, 2026). Notably, four healthcare workers died within four days at Mongbwalu General Referral Hospital, indicating severe breaches in infection prevention and control. Demographic data indicate that most suspected cases are aged 20–39 years, with females accounting for more than 60% of cases, suggesting substantial household and caregiver transmission dynamics. Contact-tracing efforts remain compromised by insecurity; as of May 15, only 65 contacts had been listed, with 15 classified as high-risk. ^[21]

Cross-border cases in Uganda linked to travel from DRC indicate geographic spread potential. The ongoing security situation in Ituri Province substantially complicates outbreak response efforts, limiting access to affected populations and disrupting supply chains for diagnostics and PPE.

Ebola viruses preferentially infect cells of myeloid lineage, including monocytes, macrophages, and dendritic cells. ^{[2], [10]} This cellular tropism pattern has profound implications for disease pathogenesis. Macrophages and dendritic cells, which normally function as sentinels of innate immunity, become primary replication sites for the virus. The widespread infection of these antigen-presenting cells results in both direct cytopathic effects and a profound dysregulation of immune responses.

Following initial infection, the virus replicates locally within tissue macrophages. Within days, viremia develops as infected mononuclear phagocytes release newly assembled virions into the bloodstream. ^[19] Viral replication is accompanied by dramatic increases in intracellular viral RNA and protein, often reaching titers up to 10⁸–10⁹ genome copies per milliliter in severely ill patients.

A critical feature of EVD pathogenesis is the delay in adaptive immune response development. ^[10] Antibody responses typically do not become detectable until days 8–10 of illness, and neutralizing antibodies often appear even later. This temporal gap between viral replication and antibody-mediated immunity allows unrestricted virus amplification during the crucial early phase.

The hallmark of severe EVD is a dysregulated pro-inflammatory response characterized by markedly elevated levels of cytokines including TNF-α, IL-1, IL-6, IL-8, IL-10, and IFN-γ. ^{[2], [10]} This "cytokine storm" does not represent appropriate control of the virus; rather, it reflects paradoxical immune activation despite simultaneous failure of effective antiviral immunity.

This dysregulated cytokine response directly contributes to the most severe complications of EVD. TNF-α, IL-1, and IL-6 act on vascular endothelial cells, increasing vascular permeability and promoting leukocyte extravasation. ^[2] IL-8 and other chemokines drive recruitment of additional inflammatory cells, amplifying the inflammatory cascade. The result is diffuse vascular leakage, leading to hypovolemia, hypotension, and shock. Simultaneously, elevated TNF-α triggers apoptosis of uninfected lymphocytes (particularly T cells), further impairing adaptive immune responses at the critical moment when such responses are most needed.

Paradoxically, surviving patients often mount delayed but eventually effective adaptive immune responses, including both CD8+ T cell responses targeting viral epitopes and neutralizing antibody responses. ^[10]

Direct infection of endothelial cells represents another important aspect of EVD pathogenesis, recently confirmed through autopsy studies. ^[19] Once infected, endothelial cells undergo apoptosis and detachment, resulting in loss of vascular integrity. The loss of endothelial barrier function combines with activated tissue factor release and dysregulation of coagulation to produce a prothrombotic state.

Patients with severe EVD typically exhibit disseminated intravascular coagulation (DIC) with both consumption of coagulation factors and platelets, and simultaneous ongoing thrombin generation. ^[19] The result is a state of simultaneous bleeding and clotting—a state that presents clinical challenges in management.

Hemorrhagic manifestations occur in only a subset of severe EVD cases (approximately 20–40%), yet the presence of hemorrhage is associated with extremely poor prognosis. ^[2] Death in many patients results from hypovolemic shock and multi-organ failure secondary to vascular leakage, not from hemorrhagic blood loss per se.

Timely and accurate diagnosis of Ebola virus disease is critical for outbreak response. ^[19] The clinical presentation of EVD during the early febrile phase is non-specific and overlaps substantially with other febrile illnesses endemic to Africa, including malaria, typhoid, dengue, and Lassa fever. Thus, laboratory confirmation is essential.

Reverse transcription polymerase chain reaction (RT-PCR) targeting viral RNA is the gold standard for EVD diagnosis. ^{[1], [19]} Modern real-time RT-PCR assays can detect as few as 1–10 viral RNA copies per milliliter, providing exquisite sensitivity. These assays typically target conserved regions of the L gene (polymerase) or the NP gene, and some multiplex assays can simultaneously amplify targets from multiple Ebola species, enabling species identification.

A multiplex RT-PCR assay capable of discriminating among EBOV, SUDV, BDBV, and TAFV in a single reaction has been developed and field-validated. ^[22] Next-generation sequencing (NGS), while not suitable for rapid clinical diagnosis, has become increasingly important for phylogenetic analysis and outbreak source-tracing. ^[1]

Enzyme-linked immunosorbent assay (ELISA) for Ebola virus antigens (typically targeting NP and GP) can provide rapid diagnosis in 2–4 hours. ^[19] However, antigen ELISA sensitivity is lower than RT-PCR, particularly in the early febrile phase. Sensitivity improves as viral loads increase during the critical phase.

Immunochromatographic assays (rapid diagnostic tests, RDTs) based on lateral-flow immunochromatography provide results in 15–20 minutes. ^[22] Several validated assays demonstrate greater than 90% sensitivity and specificity after day 5 of illness. The advantage of antigen-based approaches lies in their simplicity, speed, and minimal infrastructure requirements. However, a negative antigen test does not exclude EVD, and molecular confirmation should be pursued for any suspected case.

Antibody-based diagnosis becomes relevant from approximately day 6–8 of illness, when specific IgM responses develop. ^{[18], [19]} By day 10–12, IgG antibodies are detectable in most patients. Serological testing is particularly valuable in late convalescence and in retrospective outbreak investigations where patients may present weeks after illness onset.

Serological assays are essential for identifying convalescent plasma donors, who can provide antibody-containing blood products for potential therapeutic use. One caveat to serological diagnosis in outbreak settings is the potential for false-positive results due to cross-reactivity with other filoviruses.

Currently, no FDA-approved antiviral drugs or monoclonal antibodies specifically targeting Bundibugyo ebolavirus are available. ^{[14], [15]} Thus, management of EVD remains fundamentally centered on intensive supportive care. Ironically, despite the absence of specific antivirals, early studies and retrospective analyses from large outbreaks suggest that optimized supportive care alone can substantially improve survival, particularly if initiated early in the course of illness.

Critical supportive care measures include:

• Aggressive fluid resuscitation to maintain hemodynamic stability (fluid losses often exceed 5–10 liters) ^[19]
• Electrolyte correction (hypokalemia, hypomagnesemia)
• Oxygenation maintenance through supplemental oxygen and mechanical ventilation
• Blood transfusion for severe anemia or ongoing hemorrhage
• Renal replacement therapy (dialysis) for renal failure in resource-rich settings
• Glucose monitoring and management of hyperglycemia

Given the lack of effective antivirals, infection prevention and control (IPC) measures represent perhaps the most critical intervention for managing EVD outbreaks. ^[22] Standard precautions include hand hygiene, use of gloves and eye protection for patients with suspected EVD, and proper use of respiratory protection when indicated. Contact precautions (dedicated care spaces, use of full-body PPE including gowns, gloves, and respiratory protection) are essential for managing confirmed EVD cases.

Additional critical IPC measures:

• Safe injection practices (estimated transmission risk: 20–40% per needle-stick injury) ^[22]
• Safe specimen handling in biosafety level 4 (BSL-4) facilities or enhanced BSL-3
• Environmental disinfection of surfaces contaminated with blood or body fluids
• Safe disposal of sharps and hazardous waste
• Safe burial practices (avoiding direct contact with deceased bodies)

Several investigational antiviral compounds and immunotherapies have been evaluated for EBOV infection, though clinical data for BDBV remains limited. ^{[15], [17]} Monoclonal antibodies targeting Ebola glycoprotein (GP) have been developed and evaluated for EBOV. INMAZEB (atoltivimab–maftivimab–odesivimab; a combination of three monoclonal antibodies) and Ebanga (ansuvimab-zykl), a single monoclonal antibody, both demonstrated substantial efficacy in reducing mortality and have been FDA-approved for EBOV. ^[15] However, cross-neutralization against BDBV remains uncertain.

Convalescent plasma (CP) from survivors of EVD, containing virus-specific antibodies, has been proposed as a source of passive immunotherapy. ^[19] Case reports and small series suggest potential benefit, though controlled trials have yielded mixed results. Current recommendations remain cautious regarding CP use, though it may be considered in resource-limited settings where other specific therapeutics are unavailable.

Vaccination represents the most effective long-term strategy for EVD prevention, yet the 2026 BDBV epidemic occurs in the notable absence of a licensed species-specific vaccine. ^[16] Two EBOV vaccines have been developed and deployed:

However, these vaccines were designed and tested specifically against EBOV. ^[16] In vitro studies examining cross-neutralization of BDBV by rVSV-ZEBOV or Ad26.ZEBOV/MVA-ZEBOV vaccine-induced antibodies have yielded modest results, with limited cross-reactive neutralizing antibodies. ^[11] Whether vaccinating contacts and healthcare workers with EBOV vaccines would provide meaningful protection against BDBV remains an open question.

Experimental BDBV vaccines have been tested in non-human primates, but no licensed product exists. ^{[11], [16]} Polyvalent vaccines expressing GP from multiple Ebola species have been explored in preclinical and early-phase clinical studies but have not yet advanced to licensure. The current epidemic underscores the urgent need for development and clinical evaluation of vaccines targeting BDBV and other less common species. ^[13]

The 2026 Bundibugyo ebolavirus epidemic in the DRC and Uganda represents a critical moment in filoviral epidemiology and highlights persistent gaps in global health preparedness for emerging infectious diseases. ^[23] This outbreak follows the 16th Ebola outbreak in DRC (Bulape, Kasai Province, September–December 2025), demonstrating the country's persistent vulnerability to filoviral emergence. Despite two decades of accumulated knowledge regarding Ebola virology and pathogenesis since the 1976 outbreaks, and despite successful development of efficacious vaccines and therapeutic candidates for EBOV, the emergence of BDBV as a cause of a recognized PHEIC demonstrates that preparedness remains incomplete.

The fundamental challenge posed by the BDBV outbreak is not ignorance of the virology of Ebola viruses. The molecular biology of Ebola, including the structural and functional roles of the seven viral proteins, the mechanisms of immune evasion, the cellular tropism patterns, and the pathogenetic mechanisms driving disease, are now substantially understood. Rather, the challenge lies in the gap between scientific knowledge and practical implementation of prevention and control measures in resource-constrained settings experiencing concurrent security challenges.

The absence of a licensed species-specific vaccine for BDBV represents a critical gap in outbreak response capacity. ^[11] While accelerated vaccine development programs for novel pathogens have been demonstrated during the COVID-19 pandemic, analogous efforts for BDBV have not yet materialized. This reflects several realities: (1) BDBV infection, while severe, historically affects smaller numbers of people compared to EBOV; (2) commercial incentives for vaccine development are limited for a pathogen with sporadic outbreaks; and (3) regulatory pathways for rapid vaccine approval in outbreak settings are still being developed.

Controlling the current BDBV epidemic and preventing future filoviral pandemics require sustained investment in:

• Global health infrastructure development
• Healthcare worker education and training
• Diagnostic capacity development
• Pandemic preparedness at the local, national, and international levels

As the world continues to grapple with the profound disruptions wrought by COVID-19, the emergence of another pathogenic RNA virus demanding immediate, coordinated, and resource-intensive responses serves as a sobering reminder that pandemic preparedness remains an unfinished agenda.

Advancing research on Ebola virus requires validated, high-quality reagents and diagnostic tools. Specialized research suppliers provide a comprehensive portfolio of research-grade materials to support molecular, immunological, and diagnostic studies of Ebola viruses, including materials for both Zaire and Bundibugyo species.